Online inquiry

IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2695MR)

This product GTTS-WQ2695MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets SOST gene. The antibody can be applied in Low bone mineral density research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_025237.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 50964
UniProt ID Q9BQB4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ2695MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ11557MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MG-A271
GTTS-WQ44MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 2857916
GTTS-WQ7972MR IVTScrip™ mRNA-Anti-IL7R, GX-17(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GX-17
GTTS-WQ3002MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Angiocept
GTTS-WQ11748MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-1308
GTTS-WQ12062MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MOR-00208
GTTS-WQ1308MR IVTScrip™ mRNA-Anti-MET, ABT-700(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-700
GTTS-WQ15827MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb-18087
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW